Carbamazepine is a voltage-gated sodium-channel blocker used as a first-line antiepileptic for focal and generalised tonic-clonic seizures, and as the primary pharmacological treatment for trigeminal neuralgia. Simson Pharma's Carbamazepine reference standard and extensive impurity panel (including the pharmacologically active 10,11-epoxide metabolite) support the comprehensive compendial testing this long-established antiepileptic demands.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Carbamazepine Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.